Immunology and Microbiology
Uropathogenic Escherichia Coli
100%
Urinary Tract
97%
Staphylococcus Aureus
65%
Severe Acute Respiratory Syndrome Coronavirus 2
47%
Porcine Model
44%
Escherichia coli
44%
Biofilm
35%
COVID-19
28%
Neutralization
25%
Pig
21%
Omicron Coronavirus Variant
16%
Infectious Agent
15%
Filamentation
15%
Fimbria
14%
Animal Experiment
14%
Micturition
11%
Antimicrobial Resistance
10%
Monoclonal Antibody
10%
Inoculum
10%
Blood Plasma
9%
Booster Dose
9%
Cytotoxicity
9%
Colony Forming Unit S
8%
Antibacterial Activity
8%
Abdominal Pressure
8%
Mediator
8%
Urine Sampling
8%
Viral Load
8%
Macrophage
8%
Bacterial Count
8%
Complement Lectin Pathway
7%
Complement Activation
7%
Dynamics
7%
Minimum Inhibitory Concentration
7%
Immunocompromised Patient
7%
Thioridazine
7%
Antimicrobial Peptides
7%
Breed
7%
Raman Spectroscopy
7%
Aspergillus
7%
4 [3 (1h Tetrazol 5 Yl) 8 Coumarinyloxy]butyric Acid
7%
Biomechanics
7%
Matrix Protein
7%
Alpha-2-Macroglobulin
7%
Bladder Emptying
7%
Bone Structure
7%
Medline
7%
Bladder Mucosa
7%
Antibiotic Sensitivity
7%
Lectin Pathway
7%
Pharmacology, Toxicology and Pharmaceutical Science
SARS Coronavirus
35%
Staphylococcus Aureus
27%
Infection
27%
Antiinfective Agent
24%
Opiate Peptide
21%
Prodrug
21%
Escherichia coli
16%
Thioridazine
14%
Dicloxacillin
14%
Antibiotics
13%
Effusion
11%
P-Glycoprotein
10%
Antivirus Agent
10%
Antibacterial Activity
10%
CYP3A4
10%
Immunocompromised Patient
10%
Uropathogenic Escherichia Coli
8%
Porcine Model
8%
Drug Delivery System
8%
Digestant
8%
Bloodstream Infection
8%
Surgical Infection
7%
Graft Infection
7%
Urinary Tract Infection
7%
Aspergillus
7%
Fucoidan
7%
RNA 23S
7%
Pleuromutilin Antibiotic Agent
7%
Enkephalin[2 Dextro Alanine 5 Dextro Leucine]
7%
Staphylococcal Infection
7%
Malignant Neoplasm
7%
Ovine Model
7%
Hyperplasia
7%
Polypeptide Antibiotic Agent
7%
Laminaria
7%
Peptidomimetic Agent
7%
Povidone
7%
1 Vinyl 2 Pyrrolidinone
7%
Glycoprotein
7%
Absorption-Distribution-Metabolism-Excretion Toxicity
7%
Blood-Brain Barrier
7%
Pharmacokinetics
7%
Pleuromutilin
7%
Plasma Protein Binding
7%
Bioavailability
7%
Cytotoxicity
7%
Gram Positive Infection
7%
Messenger RNA
7%
Monotherapy
7%
Remdesivir
7%
Medicine and Dentistry
Severe Acute Respiratory Syndrome Coronavirus 2
28%
Urinary Tract Infection
24%
Bladder
23%
Urinary Tract
17%
Infection
16%
COVID-19
15%
Immunocompromised Patient
14%
Drug Delivery System
14%
Injury
9%
Ex Vivo
9%
Urinary System
9%
Residual Urine
8%
Microtrauma
8%
Residual Volume
8%
Antiinfective Agent
8%
In Vitro
8%
Mitomycin
7%
Surgical Infection
7%
Catheterization
7%
Urination
7%
Virus Shedding
7%
Alpha 2 Macroglobulin
7%
Mediator
7%
Diabetic Nephropathy
7%
Mesangial Cell
7%
Kidney Tissue
7%
Micturition
6%
Intermittent Catheterisation
5%
